Zydus grants Sun Pharma semi-exclusive rights to co-market the product in India, with Sun Pharma marketing the drug as RYTSTAT®
Flattish sales volumes likely during the quarter.
Order values are categorized as significant, large, major and mega
Steady performance likely on the cards.
Strong show on margins, earnings is expected from the company.
The issue is entirely OFS (offer for sale).
However, the net NPA ratio grew to 0.60% in the second quarter, up from 0.55% in the June 2023 period.
Analysts of IIFL Capital Services expect 4G pre-paid tariff hikes only in FY25 and largely maintain estimates.
Revenue reached a record high of Rs 6,880.20 crore, up 9% from the Rs 6,305.70 crore earned in the same period last year.
The GoI-backed company has registered a rise in net profit both sequentially and in YoY terms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Reg. No. INM000010940, SEBI RA Regn. No: INH000000248, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
